CN104098491B - 一种乙酰半胱氨酸化合物及含有该化合物的吸入用乙酰半胱氨酸溶液 - Google Patents
一种乙酰半胱氨酸化合物及含有该化合物的吸入用乙酰半胱氨酸溶液 Download PDFInfo
- Publication number
- CN104098491B CN104098491B CN201410340262.2A CN201410340262A CN104098491B CN 104098491 B CN104098491 B CN 104098491B CN 201410340262 A CN201410340262 A CN 201410340262A CN 104098491 B CN104098491 B CN 104098491B
- Authority
- CN
- China
- Prior art keywords
- acetylcysteine
- mixed solvent
- mucolyticum
- acid compound
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title claims abstract description 114
- 239000003172 expectorant agent Substances 0.000 title claims abstract description 73
- 229960004308 acetylcysteine Drugs 0.000 title claims abstract description 55
- 150000001875 compounds Chemical class 0.000 title abstract description 56
- 239000002253 acid Substances 0.000 title abstract description 44
- 239000013078 crystal Substances 0.000 claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 10
- 230000005260 alpha ray Effects 0.000 claims abstract description 8
- 238000005259 measurement Methods 0.000 claims abstract description 8
- QZDVRJFYQSCEKN-UHFFFAOYSA-N n-(1,1-dioxothiolan-3-yl)formamide Chemical compound O=CNC1CCS(=O)(=O)C1 QZDVRJFYQSCEKN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000012046 mixed solvent Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 20
- 239000011260 aqueous acid Substances 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 230000001133 acceleration Effects 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 229910017488 Cu K Inorganic materials 0.000 claims description 7
- 229910017541 Cu-K Inorganic materials 0.000 claims description 7
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 2
- BQFCCCIRTOLPEF-UHFFFAOYSA-N chembl1976978 Chemical compound CC1=CC=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 BQFCCCIRTOLPEF-UHFFFAOYSA-N 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- VKZDBINLDWJXBJ-WCCKRBBISA-N (2R)-2-acetamido-3-sulfanylpropanoic acid hydrate Chemical compound O.CC(=O)N[C@@H](CS)C(O)=O VKZDBINLDWJXBJ-WCCKRBBISA-N 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 36
- 239000000243 solution Substances 0.000 description 33
- 239000003814 drug Substances 0.000 description 27
- 206010036790 Productive cough Diseases 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 206010011224 Cough Diseases 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 230000003419 expectorant effect Effects 0.000 description 15
- 239000008215 water for injection Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 230000002411 adverse Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000006392 deoxygenation reaction Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000005303 weighing Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- 229910003460 diamond Inorganic materials 0.000 description 5
- 239000010432 diamond Substances 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- -1 half Cystine compound Chemical class 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- WWHDFTWNMBCRIK-UHFFFAOYSA-N 2-acetylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(=O)C1=CC(=O)C=CC1=O WWHDFTWNMBCRIK-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 235000005324 Typha latifolia Nutrition 0.000 description 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940021715 acetylcysteine injection Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 244000118869 coast club rush Species 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 150000001944 cysteine derivatives Chemical group 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
样品 | 引湿性(%) |
120401 | 9.52 |
120402 | 9.49 |
120403 | 9.51 |
120501 | 9.47 |
120502 | 9.48 |
120503 | 9.46 |
对照1 | 16.26 |
对照2 | 16.27 |
对照3 | 16.29 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410340262.2A CN104098491B (zh) | 2014-07-17 | 2014-07-17 | 一种乙酰半胱氨酸化合物及含有该化合物的吸入用乙酰半胱氨酸溶液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410340262.2A CN104098491B (zh) | 2014-07-17 | 2014-07-17 | 一种乙酰半胱氨酸化合物及含有该化合物的吸入用乙酰半胱氨酸溶液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104098491A CN104098491A (zh) | 2014-10-15 |
CN104098491B true CN104098491B (zh) | 2016-08-17 |
Family
ID=51667077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410340262.2A Active CN104098491B (zh) | 2014-07-17 | 2014-07-17 | 一种乙酰半胱氨酸化合物及含有该化合物的吸入用乙酰半胱氨酸溶液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104098491B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104667256B (zh) * | 2015-03-18 | 2017-05-03 | 江苏威克斯医疗科技有限公司 | 一种鼻腔粘膜纤毛护理冲洗液及其用途 |
CN104800854B (zh) * | 2015-05-13 | 2017-09-22 | 武汉武药科技有限公司 | 一种吸入用乙酰半胱氨酸溶液及其制备方法 |
CN111870591B (zh) * | 2020-09-16 | 2022-07-26 | 海南斯达制药有限公司 | 一种控制乙酰半胱氨酸溶液硫化氢含量的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1711998A (zh) * | 2005-03-30 | 2005-12-28 | 杭州华科生物医药技术有限公司 | 一种稳定的、pH值近中性的多规格乙酰半胱氨酸溶液及其制备方法 |
CN101028252A (zh) * | 2007-02-15 | 2007-09-05 | 何晶 | 一种注射用乙酰半胱氨酸粉针药物组合物及其制备方法 |
EP1902706A1 (en) * | 2006-09-25 | 2008-03-26 | Divasa-Farmavic, S.A. | Stable pharmaceutical compositions of tetracyclines in solution, method for obtaining them and their uses |
CN101585792A (zh) * | 2009-06-12 | 2009-11-25 | 中国科学院亚热带农业生态研究所 | 一种仔猪肠道屏障功能调控物质-n-乙酰半胱氨酸的制备方法 |
CN103102295A (zh) * | 2012-03-28 | 2013-05-15 | 新沂市汉菱生物工程有限公司 | 一种乙酰半胱氨酸的生产方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103027891A (zh) * | 2012-11-25 | 2013-04-10 | 天津坤健生物制药有限公司 | 用于治疗口腔溃疡的乙酰半胱氨酸含漱液及制备方法 |
-
2014
- 2014-07-17 CN CN201410340262.2A patent/CN104098491B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1711998A (zh) * | 2005-03-30 | 2005-12-28 | 杭州华科生物医药技术有限公司 | 一种稳定的、pH值近中性的多规格乙酰半胱氨酸溶液及其制备方法 |
EP1902706A1 (en) * | 2006-09-25 | 2008-03-26 | Divasa-Farmavic, S.A. | Stable pharmaceutical compositions of tetracyclines in solution, method for obtaining them and their uses |
CN101028252A (zh) * | 2007-02-15 | 2007-09-05 | 何晶 | 一种注射用乙酰半胱氨酸粉针药物组合物及其制备方法 |
CN101585792A (zh) * | 2009-06-12 | 2009-11-25 | 中国科学院亚热带农业生态研究所 | 一种仔猪肠道屏障功能调控物质-n-乙酰半胱氨酸的制备方法 |
CN103102295A (zh) * | 2012-03-28 | 2013-05-15 | 新沂市汉菱生物工程有限公司 | 一种乙酰半胱氨酸的生产方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104098491A (zh) | 2014-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101836953B (zh) | 盐酸氨溴索组合物注射液 | |
CN104027326B (zh) | 盐酸氨溴索雾化吸入剂及其制备方法和应用 | |
CN104098491B (zh) | 一种乙酰半胱氨酸化合物及含有该化合物的吸入用乙酰半胱氨酸溶液 | |
CN103880910A (zh) | 一种环黄芪醇的制备方法及其用途 | |
CN105193707A (zh) | 一种盐酸氨溴索口服溶液及其制备方法 | |
CN103087042B (zh) | 西他沙星的盐及制药用途 | |
CN105250216A (zh) | 适宜雾化吸入用的盐酸氨溴索注射液 | |
CN106667902A (zh) | 一种稳定的盐酸氨溴索注射液及其制备方法 | |
CN102525963B (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
CN102860980A (zh) | 一种罗库溴铵注射液的制备方法 | |
CN102872462B (zh) | 一种盐酸氨溴索组合物及其制剂 | |
CN104208028A (zh) | 一种含有法罗培南钠的颗粒剂及其制备方法 | |
CN103951679B (zh) | 一种头孢哌酮钠化合物及其药物组合物 | |
CN103169674A (zh) | 注射用奥美拉唑钠冷冻干燥粉针剂 | |
CN106109401A (zh) | 一种高纯度氨甲环酸注射剂及其制备方法以及在心脏外科手术体外循环围术期适应症的应用 | |
CN104086531B (zh) | 一种埃索美拉唑钠化合物及其药物组合物 | |
CN103735498B (zh) | 一种果糖二磷酸钠注射液的制备方法 | |
CN104173304B (zh) | 林可霉素分散片 | |
CN102258504A (zh) | 一种复方硫酸沙丁胺醇和盐酸氨溴索吸入溶液 | |
CN103655460B (zh) | 一种含氨曲南的注射用药物组合物及其制备方法和用途 | |
CN106806418A (zh) | 一种双黄连雾化吸入用溶液制剂及其制备方法 | |
CN104644632A (zh) | 含有阿齐沙坦和苯磺酸氨氯地平的口服片剂及其制备方法 | |
CN105520955A (zh) | 一种羧基麦芽糖铁药用组合物及其制备方法 | |
CN112569210A (zh) | 一种吸入用马昔腾坦溶液及其制备方法 | |
CN106913535A (zh) | 一种ddp-4抑制剂药物口崩片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Huang Bendong Inventor after: Xu Yan Inventor after: Xie Anyun Inventor after: Jiang Yinmei Inventor before: Jiang Yinmei |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161018 Address after: 139 No. 410203 Hunan province Changsha Wangcheng Tongguanshan circular economy industrial base Tongguan Road Patentee after: Hunan Warner Pharmaceutical Co., Ltd. Address before: 3 410007 Hua Sheng garden, 398 North Shaoshan Road, Hunan, Changsha 438, China Patentee before: Jiang Yinmei |